Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 9/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NPM1 | P06748 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531805 | 1.00 | NT5E (0.46) | NT5EACHEHTTPTGESBACE1 | |
| SCHEMBL31218411 | 0.84 | NT5E (0.64) | NT5EACHEHTTCYP1A2CYP2C19 | |
| SCHEMBL4015829 | 0.84 | NT5E (0.64) | NT5EACHEHTTCYP1A2CYP2C19 | |
| SCHEMBL11346168 | 0.81 | BACE1 (0.53) | NT5EACHEHTTPTGESBACE1 | |
| SCHEMBL31494112 | 0.81 | ACHE (0.41) | NT5EACHEHTTPTGESBACE1 | |
| SCHEMBL8135661 | 0.81 | ACHE (0.41) | NT5EACHEHTTPTGESBACE1 | |
| SCHEMBL7424524 | 0.81 | CYP2C19 (0.49) | NT5EACHEHTTPTGESBACE1 | |
| SCHEMBL8141883 | 0.79 | ACHE (0.40) | NT5EACHEHTTPTGESBACE1 | |
| SCHEMBL5638415 | 0.79 | POLB (0.50) | ACHEMPO | |
| SCHEMBL30415489 | 0.79 | POLB (0.50) | ACHEMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066335-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | UNIVERSITY OF COPENHAGEN (DK) | 2025-02-27 | — | — | US | disclosed |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-20 | — | — | US | disclosed |
| EP-4355743-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | University of Copenhagen (DK) | 2024-04-24 | — | — | EP | disclosed |
| EP-4329757-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117561063-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4308564-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20150344521-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9145441-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145441-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145441-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2861604-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | Gilead Sciences, Inc. (US) | 2015-04-22 | — | — | EP | disclosed |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| WO-2013185103-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-12-12 | — | — | WO | disclosed |
| WO-2002026713-A1 | ANTIPARASITIC COMPOUNDS | KING'S COLLEGE LONDON (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | NT5E 4242/4885ACHE 3520/4885HTT 4373/4885 |
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | NT5E 2543/4885ACHE 2097/4885HTT 4443/4885 |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | NT5E 4775/4885ACHE 4813/4885HTT 1429/4885 |
| US-20250066335-A1 | POLYSUBSTITUTED 4-HYDROXYPYRIDINE AND 4-HYDROXYQUINOLINE DERIVATIVES AS GPR84 ANTAGONISTS | GPR84, GPR88, GPR65 | NT5E 2651/4885ACHE 2478/4885HTT 659/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | NT5E 321/4885ACHE 206/4885HTT 19/4885 |
| US-20150344521-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | NT5E 4242/4885ACHE 3520/4885HTT 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.